Sun Pharma Laboratories Ltd. Vs Finecure Pharmaceuticals Ltd.
**Date of Judgment:** 01.07.2026
**Case No.:** FAO(OS) (COMM) 200/2023
**Neutral Citation:** 2026:DHC:4530-DB
**Court:** High Court of Delhi
**Hon'ble Judge:** Justice Manmeet Pritam Singh Arora (for the Division Bench)
The court considered a dispute concerning trademark infringement of a registered pharmaceutical brand name. The case arose from allegations that the respondents' mark 'PANTOPACID' for Pantoprazole-based acidity medicine infringed the appellant's registered mark 'PANTOCID' in use since 1999. The principal question before the Court was whether interim injunction should be granted despite findings of deceptive similarity, given challenges to registration validity, alleged concealment, and delay.
After examining the material on record and the submissions of the parties, Justice Manmeet Pritam Singh Arora observed that the single judge erred in disregarding the prima facie validity of the appellant's registration under Section 31 of the Trade Marks Act, 1999, and in holding non-disclosure of prior proceedings as fatal, especially since Takeda’s conflicting registration lapsed. The Court held that in cases of established infringement of registered trademarks for identical drugs, injunction ordinarily follows, emphasizing public interest in avoiding confusion and the limited scope for challenging validity at interim stage absent substantial grounds.
Accordingly, the Court allowed the appeal, set aside the single judge's refusal of injunction, granted interim restraint against the respondents' use of 'PANTOPACID' and similar marks, with limited sell-off period, and directed expeditious trial.
[Disclaimer: Readers are advised not treat this as a substitute for legal advise as it is based on limited information and is intended solely for general informational purposes.]
### Introduction
In the highly regulated pharmaceutical sector, where brand confusion can have serious health implications, trademark protection plays a vital role in safeguarding consumer trust and business investments. This Delhi High Court Division Bench decision in a long-running battle over similar-sounding acidity drug brands underscores the strong presumptive validity of registered trademarks and the court's preference for granting injunctions in clear cases of infringement. The ruling is particularly significant for pharmaceutical companies, IP practitioners, and regulators, as it clarifies when prior challenges or delays should not bar interim relief, while reinforcing public interest considerations in medicine branding.
### Factual and Procedural Background
Sun Pharma Laboratories has been marketing Pantoprazole-based medicine under the trademark 'PANTOCID' since 1999, with registration dating back to an application in 1998 that was granted in 2012. The company claims substantial sales and reputation for this Schedule H drug used in treating acidity and related conditions. Finecure Pharmaceuticals adopted 'PANTOPACID' around 2007 and filed for registration in 2009, which Sun opposed. Sun discovered market presence of the rival product in April 2023 and filed a suit for permanent injunction. The single judge found deceptive similarity and infringement but refused interim relief citing validity challenges, alleged non-disclosure, and delay. Sun appealed this order.
### Dispute Before the Court
The central questions were whether Sun Pharma was entitled to an interim injunction against Finecure's use of 'PANTOPACID' given the finding of infringement, and whether issues like a prior similar registration by another entity (Takeda), alleged concealment of correspondence, and delay in filing the suit justified denying relief. Sun argued its registered rights were presumptively valid, infringement was clear, and prior proceedings had concluded in its favor. Finecure contended the registration faced credible challenge, Sun suppressed material facts, and its delay allowed Finecure to build business, tilting balance of convenience against injunction.
### Reasoning and Analysis of the Court
The Court relied on principles from the Trade Marks Act, 1999, particularly Sections 11, 28, 29, and 31, which grant registered proprietors exclusive rights and presume validity of registration. It emphasized that civil courts should not lightly disregard registrations absent substantial challenges like fraud. Key precedents included *Midas Hygiene Industries Pvt. Ltd. v. Sudhir Bhatia* (2004) on injunctions following infringement, *Cadila Health Care Ltd. v. Cadila Pharmaceuticals Ltd.* (2001) on public interest in pharmaceutical cases, and *Lupin Ltd. v. Johnson & Johnson* (2014) on when validity can be questioned.
The Division Bench found the single judge erred by over-relying on a lapsed Takeda registration (removed in 2019) to doubt Sun's rights. Opposition proceedings and correspondence from 2010 were adequately disclosed through the pending opposition filing. Delay alone does not defeat injunctions in infringement cases, especially with ongoing opposition. Sales data showed Sun's massive turnover versus Finecure's modest figures, negating claims of Finecure as a "formidable player." Public interest in preventing confusion for identical drugs favored injunction. Invoices' genuineness was left for trial.
### Final Decision of the Court
The Division Bench allowed the appeal. It set aside the single judge's refusal of injunction, granted interim restraint against Finecure's use of 'PANTOPACID' and similar marks, permitted limited sell-off of existing stock, and directed expeditious framing of issues and trial in the suit. Perjury proceedings regarding documents were left open for the single judge.
### Point of Law Settled
The judgment reaffirms that a registered trademark enjoys strong presumptive validity under Section 31, and interim injunctions should ordinarily follow established infringement, particularly for pharmaceuticals, unless a substantial challenge exists. It clarifies that lapsed prior marks or historical correspondence need not bar relief if disclosed through statutory proceedings. This will guide future pharma IP cases, discouraging frivolous validity challenges at interim stages and prioritizing consumer safety.
**Case Details:**
**Title of the Case:** Sun Pharma Laboratories Ltd. vs Finecure Pharmaceuticals Ltd. & Ors.
**Date of Judgment/Order:** 01.07.2026
**Case Number:** FAO(OS) (COMM) 200/2023
**Neutral Citation:** 2026:DHC:4530-DB
**Name of Court:** High Court of Delhi
**Name of Hon'ble Judge:** Justice Manmeet Pritam Singh Arora (Division Bench)
**Written By:** Advocate Ajay Amitabh Suman, IP Adjutor [Patent and Trademark Attorney], High Court of Delhi
**Disclaimer:** Images used herein do not reflect actual images used in Judgement and that the same are for illustrative purpose only. Readers are advised not to treat this as substitute for legal advice as it may contain errors in perception, interpretation, and presentation.
**Suggested SEO Titles:**
1. Delhi High Court Grants Injunction to Sun Pharma in 'PANTOCID' Trademark Infringement Case
2. Pharma Trademark Battle: Delhi HC Allows Appeal Against Denial of Interim Relief
3. Registered Trademark Validity and Injunctions: Key Lessons from Sun Pharma Judgment
4. Deceptive Similarity in Drug Brands: Delhi Division Bench Ruling on Pantoprazole Marks
5. Delay Not a Bar to Injunction in Trademark Infringement: Sun Pharma vs Finecure Analysis
6. Public Interest in Pharmaceutical Trademarks: Delhi HC Emphasizes Consumer Protection
7. Clean Hands and Prior Registrations in IP Disputes: 2026 Delhi High Court Verdict
8. Sun Pharma Wins Appeal: Injunction Against 'PANTOPACID' Upheld by Division Bench
9. Section 31 Trade Marks Act Presumption: Delhi HC Clarifies Scope in Pharma Cases
10. Balancing Business Growth and IP Rights: Analysis of Sun Pharma Laboratories Appeal
**Suggested SEO Tags:** trademark infringement pharmaceuticals, PANTOCID trademark, PANTOPACID mark, Delhi High Court IP appeal, registered trademark validity, interim injunction drugs, deceptive similarity medicine brands, Sun Pharma judgment, Trade Marks Act Section 31, Cadila judgment application, AdvocateAjayAmitabhSuman, IPAdjutor
**Headnote of the Judgment:** In FAO(OS)(COMM) 200/2023 before the Delhi High Court, Sun Pharma appealed the single judge's refusal of interim injunction despite finding 'PANTOPACID' infringed its registered 'PANTOCID' mark for Pantoprazole drugs. The Division Bench allowed the appeal, holding the registration presumptively valid post-lapse of prior conflicting mark, no material concealment, and public interest favoring relief. It granted injunction with limited sell-off and directed expeditious trial. (72 words)
**Prompt for Info-graphic 14:9 aspect ratio image:** Create a suitable 3d hyper realistic multicolour 8K Quality Legal info-graphic containing necessary information in graph,chart, tables , Circles , Dashboard etc. The texts be large , bold and 3D Stylish multicolour containing name of case,date of order,case no, name of court, decision and one most important principle of law laid down. Also use generic images for the product or service involved in the matter. Do not use name of any court, lawyer , tricolor, Ashoka Emblem and any other government insignia. At end of this prompt add this sentence also" Use attached image as Image of lawyer in lawyers dress at left bottom corner which should cover 20 % of entire image area.
